Stereotactic Thrombolysis With Tenecteplase for Supratentorial Intracerebral Hemorrhage
Recruiting now · Not applicable
Conditions studied: Intracerebral Haemorrhage, Minimally Invasive Treatment
In brief
This is an phase III prospective, multi-center, open-label, randomized controlled trial (RCT) with blinded endpoint assessment. It plans to enroll 768 subjects with spontaneous supratentorial intracerebral hemorrhage, who will be randomly assigned in a 1:1 ratio to the investigational arm (stereotactic minimally invasive puncture for intracerebral hemorrhage combined with TNK liquefaction drainage, single TNK dose of 0.5mg per time or the standard medical treatment group.
Key facts
- Study ID
- NCT07208097
- Run by
- Tongji Hospital
- People needed
- 768
- Starts
- 2025-10-25
- Expected to finish
- 2028-06-30
- Last updated by the study team
- 2025-12-01
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Suzhou First People's Hospital — Suzhou, Anhui, China (enrolling)
- Guizhou Medical University Affiliated Hospital — Guiyang, Guizhou, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.